FIGURE 13.
miR-326 regulates the apoptotic effect of anti-cancer drugs. A, indicated cancer cell line was transfected with control inhibitor or miR-326 inhibitor (50 nm each). 24 h after transfection, cells were treated with or without celastrol (1 μm) or Taxol (1 μm) for 24 h, followed by annexin V-FITC assays (lower panel) or Western blot analysis (upper panel). *, p < 0.05. B, same as A except that cells were transfected with control vector (1 μg) or miR-326 construct (1 μg). *, p < 0.05. C, Malme3M cells were transfected with the indicated siRNA (10 nm each). 24 h after transfection, cells were treated with celastrol (1 μm) or Taxol (1 μm) for 24 h. Cell lysates were subjected to caspase-3 activity assays (left panel). The indicated cancer cell line was treated with celastrol (1 μm) or Taxol (1 μm) for 24 h, followed by caspase-3 activity assays (right panel). **, p < 0.005; ***, p < 0.0005. D, Malme3M cells were transfected with control vector (1 μg) or miR-326 (1 μg). 24 h after transfection, cells were treated with celastrol (1 μm) or Taxol (1 μm) for 24 h, followed by caspase-3 activity assays (left panel). Malme3MR cells were transfected with the indicated inhibitor (50 nm each). 24 h after transfection, cells were treated with celastrol (1 μm) or Taxol (1 μm) for 24 h, followed by caspase-3 activity assays (right panel). *, p < 0.05; **, p < 0.005. Ctrl. Inh., control inhibitor.